Hello, Reader. For all that artificial intelligence has accomplished over the last few years, one thing it has not yet ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
Bristol Myers rallied, adding about 10% as fears about the AbbVie drug's competitive threat to its Cobenfy franchise, which it acquired as part of a $14 billion buyout of Karuna Therapeutics.
Pharmaceutical company AbbVie announced that an experimental schizophrenia drug that was key to its $8.7 billion acquisition ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
pointing to the recent Food and Drug Administration approval of the company's schizophrenia drug Cobenfy. AbbVie's emraclidine results could expand Cobenfy's first-mover advantage and ultimate market ...
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...
Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia ...
Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback